← All trials
NCT03851835
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2019
- Primary completion
- Jun 30, 2021
- Completion date
- Jun 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 1030
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CalgaryLead sponsor
- University of Western OntarioCollaborator
- University of TorontoCollaborator
- University of AlbertaCollaborator
- University of CalgaryOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of OttawaCollaborator
- University of ManitobaCollaborator
- University of MontrealCollaborator
- Alberta Children's Hospital Research InstituteCollaborator
- Children's Hospital Research Institute of ManitobaCollaborator
- Women and Children's Health Research Institute (WCHRI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.